In particular, we have previously demonstrated that melanoma cells treated with BRAF inhibitors upregulate the cell surface receptor Neuropilin-1 (NRP1), which elicits an EGFR-dependent mechanism of adaptive resistance to therapy [7]. The gene discussed is BRAF; the disease is melanoma.